Geron says new analyses support RYTELO dosing in lower-risk myelodysplastic syndromes
GERN•Geron plans to present six research posters at the American Society of Hematology meeting in New Orleans on December 12-16, 2026, including analyses supporting RYTELO’s approved dosing in lower-risk myelodysplastic syndromes.
1. Meeting presentations
Geron said it will present six research posters at the American Society of Hematology meeting, scheduled for December 12-16, 2026, in New Orleans. The presentations include analyses supporting RYTELO’s approved dosing regimen in lower-risk myelodysplastic syndromes and updated IMproveMF trial results evaluating imetelstat with ruxolitinib in myelofibrosis.
